ArticleInternational journal of women's health2013
Update on first-line treatment of advanced ovarian carcinoma.
Article in International journal of women's health, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer.International journal of environmental research and public health · 2020Trial
- Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.PloS one · 2015Trial
- Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science.Clinical and translational science · 2026Review
- Organoid models established from primary tumors and patient-derived xenograft tumors reflect platinum sensitivity of ovarian cancer patients.BMC cancer · 2025Article
- A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2025Review
- Real-world outcomes of metastatic cancer patients hospitalized at initial diagnosis: ONIRIS, a national study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer.Cancer cell · 2024Article
- Antibody-Drug Conjugates: A Start of a New Era in Gynecological Cancers.Current oncology (Toronto, Ont.) · 2024Review
- Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer.bioRxiv : the preprint server for biology · 2024Article
- Relapsed Ovarian Cancer Patients with Ascites and/or Pleural Effusion Still Benefit from Treatment: A Real-Life Study.Cancers · 2023Article
- Ovarian recurrence risk assessment using machine learning, clinical information, and serum protein levels to predict survival in high grade ovarian cancer.Scientific reports · 2023Article
- Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies.Molecular therapy oncolytics · 2023Review
- Review
- HIPEC Methodology and Regimens: The Need for an Expert Consensus.Annals of surgical oncology · 2021Review
- Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.Journal of managed care & specialty pharmacy · 2021Article
- Article
- Review
- Barriers to healthcare seeking, beliefs about ovarian cancer and the role of socio-economic position. A cross-sectional multilevel study in Dubai, a multicultural society.Journal of public health research · 2021Article
- FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo.Cancers · 2021Article
- The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.Gynecologic oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the high response rate to first-line treatment of advanced ovarian cancer, the vast majority of patients relapse. Maximal debulking surgery and chemotherapy with a platinum doublet have remained the standard of care for many years and new approaches are imperative. Recent clinical trials have given grounds for hope. Neoadjuvant chemotherapy, intraperitoneal delivery, and dose-dense strategies have all shown promising results, as has the targeting of angiogenesis. A greater understanding of the molecular landscape of ovarian cancer is helping to identify new treatment options. In this review, we will highlight the key trials and recent progress in these areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.